Clinical Trial Update: Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating venetoclax in combination with cladribine and cytarabine alternating with azacitidine plus venetoclax for newly diagnosed mono…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Monocytic Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Leustatin (cladribine)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Acute Monocytic Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING